Schering Corporation

Merck Sharp + Dohme Corp.

Intervet Inc.

Mochida Pharmaceutical Co., Ltd.

Intervet International B.v.

Merck Canada Inc.

Martin C Clasby

Samuel Chackalamannil

Yan Xia

Mariappan Chelliah

William J Greenlee

Tin-Yau Chan

Michael P Dwyer

Yuguang Wang

Zhuyan Guo

Santhosh Francis Neelamkavil

Theodros Asberom

Unmesh G Shah

Michael F Czarniecki

Fumihiko Saitoh

Hidemitsu Nishida

Tomokazu Hirabayashi

Enrico P Veltri

Keith A Eagen

Charles Jayne

Xiaobang Gao

Dario Doller

Andrew William Stamford

Bernard R Neustadt

Brian Alexander McKittrick

Yongxin Han

Duane A Burnett

Hubert B Josien

Jack D Scott

Srikanth Venkatraman

Wenxue Wu

Patrick A Pinto

Kartik M Keertikar

Linda Brockunier

Shouwu Miao

Francisco Velazquez

Thomas A Bara

Austin Chen

Sathesh P Bhat

Henry M Vaccaro

Michael P Graziano

Haiyan Pu

Murali Rajagopalan

Dipshikha Biswas

Li Wang

Karen M Marcantonio

Teddy Kosoglou

Liyuan Wang

Vince J Colandrea

Madhu Chintala

Keith Eagan

Mariappan V Chelliah

Brian Mckittrick

Li Yuan Wang

Charles L Jayne

The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.

HCV NS3 protease inhibitors

The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt or a solvate thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Morpholinone compounds as factor IXA inhibitors

Morpholinone compounds as factor IXa inhibitors

The present invention relates to novel heterocyclic compounds of Formulae (I): (Chemical formula should be inserted here as it appears on abstract in paper form) Formula (I) as disclosed herein, or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

4, 5, 6-trisubstituted pyrimidine derivatives as factor IXa inhibitors

The present invention relates to novel heterocyclic compounds of Formulae I-III; as disclosed herein or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof. Also disclosed are pharmaceutical compositions comprising said compounds, and methods for using said compounds for treating or preventing a thromboembolic disorder. 

Heterocyclic compounds as factor IXA inhibitors

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, is useful in treating diseases, disorders, or conditions such as obesity, metabolic disorders, addiction, diseases of the central nervous system, cardiovascular disorders, respiratory disorders, and gastrointestinal disorders.

Cannabinoid receptor modulators

Compounds having the structural formula I are disclosed, wherein

[object Object]

Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt thereof, wherein:

Thrombin receptor antagonists

Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein:

A compound represented by the structural formula    Also disclosed are pharmaceutical compositions and combinations containing said compounds and their uses as thrombin receptor antagonists and binders to cannabinoid receptors.

Constrained himbacine analogs as thrombin receptor antagonists

Heterocyclic-substituted tricyclics of the formulaor a pharmaceutically acceptable salts thereof, wherein:

Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Heterocyclic-substituted tricyclics of the formula

Heterocyclic-substituted tricyclics of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond;

Growing community of inventors

Scotch Plains, NJ, United States of America

Martin C Clasby